Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
2(18%)
Results Posted
117%(7 trials)
Terminated
3(27%)

Phase Distribution

Ph phase_1
7
64%
Ph phase_2
4
36%

Phase Distribution

7

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
7(63.6%)
Phase 2Efficacy & side effects
4(36.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(6)
Terminated(3)

Detailed Status

Completed6
Terminated3
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (63.6%)
Phase 24 (36.4%)

Trials by Status

completed655%
recruiting19%
terminated327%
active_not_recruiting19%

Recent Activity

2 active trials
Showing 5 of 11
recruitingphase_1

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

NCT02813135
completedphase_1

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

NCT01592370
active_not_recruitingphase_2

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

NCT03341936
completedphase_1

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

NCT01714739
completedphase_1

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

NCT03203876
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02813135Phase 1

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting
NCT01592370Phase 1

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Completed
NCT03341936Phase 2

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Active Not Recruiting
NCT01714739Phase 1

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Completed
NCT03203876Phase 1

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Completed
NCT03347123Phase 1

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Terminated
NCT02481297Phase 2

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Completed
NCT02599649Phase 2

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Terminated
NCT02399917Phase 2

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Terminated
NCT02252263Phase 1

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Completed
NCT01750580Phase 1

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11